These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38956007)

  • 21. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
    Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
    BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilars and access to biologic therapy in immune-mediated diseases.
    Vázquez-Sánchez R; Navarro-Dávila M; Herráiz ER; Merino-Bohórquez V; Borrás-Blasco J; Onteniente-González A; Iglesias-Lambarri A; Negro-Vega E
    Expert Opin Biol Ther; 2024 Jul; 24(7):647-653. PubMed ID: 38698351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilars: An Update on Clinical Trials (Review of Published and Ongoing Studies).
    Olteanu R; Zota A; Constantin M
    Acta Dermatovenerol Croat; 2017 Apr; 25(1):57-66. PubMed ID: 28511752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab-Polish Experiences.
    Barszczewska O; Piechota A
    Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34209612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis.
    Gomes T; McCormack D; Kitchen SA; Paterson JM; Mamdani MM; Proulx L; Bayliss L; Tadrous M
    CMAJ Open; 2021; 9(4):E1055-E1062. PubMed ID: 34815261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
    Aladul MI; Fitzpatrick RW; Chapman SR
    BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Revised version of the statement by the DGRh on biosimilars-update 2017].
    Braun J; Lorenz HM; Müller-Ladner U; Schneider M; Schulze-Koops H; Specker C; Strangfeld A; Wagner U; Dörner T
    Z Rheumatol; 2018 Feb; 77(1):81-90. PubMed ID: 29383440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries.
    Woo H; Shin G; Lee D; Kwon HY; Bae S
    BioDrugs; 2024 Jan; 38(1):133-144. PubMed ID: 38064144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching Among Biosimilars: A Review of Clinical Evidence.
    Allocati E; Godman B; Gobbi M; Garattini S; Banzi R
    Front Pharmacol; 2022; 13():917814. PubMed ID: 36091837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting.
    Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
    BioDrugs; 2019 Jun; 33(3):299-306. PubMed ID: 30945206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators.
    Maksabedian Hernandez EJ; Graf M; Portelli A; Shafrin J
    J Med Econ; 2022; 25(1):1118-1126. PubMed ID: 35965481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The global landscape on interchangeability of biosimilars.
    Rathore AS; Stevenson JG; Chhabra H; Maharana C
    Expert Opin Biol Ther; 2022 Feb; 22(2):133-148. PubMed ID: 33567923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.
    McClean AR; Cheng L; Bansback N; Clement F; Tadrous M; Harrison M; Law MR
    Arthritis Care Res (Hoboken); 2023 Sep; 75(9):2011-2021. PubMed ID: 36752358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19.
    Chen HH; Yemeke T; Ozawa S
    PLoS One; 2024; 19(6):e0304851. PubMed ID: 38843282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer.
    Hernandez I; Gellad WF
    J Manag Care Spec Pharm; 2020 Feb; 26(2):154-159. PubMed ID: 32011961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review.
    Allegretti JR; Brady JH; Wicker A; Latymer M; Wells A
    Adv Ther; 2024 May; 41(5):1775-1794. PubMed ID: 38466559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.
    Chang S; Hanauer S
    Curr Treat Options Gastroenterol; 2017 Mar; 15(1):53-70. PubMed ID: 28164249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study.
    Moorkens E; Vulto AG; Kent J; McClure L; Boldero R; Vanhove T; Simoens S; Huys I
    BioDrugs; 2021 Jan; 35(1):75-87. PubMed ID: 33306186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance.
    Colina M; Khodeir M; Rimondini R; Valentini M; Campomori F; Corvaglia S; Campana G
    Clin Drug Investig; 2024 Mar; 44(3):141-148. PubMed ID: 38294672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.